<p><span style="color: #262626;">在生命科學研究范式發生深刻變革的今天，以蛋白組學及其前沿分支“空間蛋白組學”為代表的技術體系，已成為驅動源頭創新與重大發現的引擎。它們不僅能夠全景式解析生理病理過程中復雜的蛋白質表達、互作與動態變化，更能將關鍵的分子事件精準定位至特定的組織微區以及單個細胞，在空間維度上還原生命的真實架構與功能網絡，為理解發育、疾病、免疫等核心生命過程提供了前所未有的視角。</span></p> <p><span style="color: #262626;">作為這一科研范式變革的堅定推動者，華盈生物始終致力于以前沿、完整、可定制的蛋白組學解決方案，賦能科學研究突破邊界。在過去的一年中，我們榮幸地見證了眾多合作伙伴在CNS及其子刊等國際頂級期刊上發表了一系列具有里程碑意義的高分研究成果。這些工作不僅解決了領域內的重要科學問題，更生動展現了以整合性、單細胞分辨率空間蛋白組學為主導的新研究范式的巨大價值——它正在系統性地揭開生命復雜性的層層面紗，引領基礎研究與臨床轉化邁向更深刻、更精準的新階段。我們期待繼續以堅實的技術平臺和深度的服務，與全國科研同仁攜手，共同繪制更加精細的生命圖譜，驅動更多源頭創新。我們甄選了若干合作伙伴的標志性創新研究成果，以資交流與研討。</span></p> <section data-tools="135編輯器" data-id="157292"> <section> <section> <section> <section> <section> <section> <section style="color: #0987e0;"><strong>0</strong><strong title="" data-original-title="">1</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作單位</strong>：復旦大學附屬中山醫院</span></p> <p><span style="color: #262626;"><strong>期刊名稱</strong>：</span><span style="color: #262626;"><strong><span style="color: #ff0000;">C</span></strong><strong><span style="color: #ff0000;">e</span></strong><strong><span style="color: #ff0000;">ll (IF:</span></strong><strong><span style="color: #ff0000;">42.5</span></strong><strong><span style="color: #ff0000;">)</span></strong></span></p> <p><span style="color: #262626;"><strong>文章標題</strong>：<strong>Cancer cells co-opt an inter-organ neuroimmune circuit to escape immune surveillance</strong></span></p> <p><span style="color: #262626;">該研究揭示了癌細胞通過ATF4-SLIT2-CGRP軸激活傷害感受神經元，遠程重塑腫瘤引流淋巴結（TDLN）的免疫狀態，從而逃避免疫監視的新機制，為聯合神經調節和免疫治療提供了理論基礎。</span></p> <p><span style="color: #0987e0;">華盈生物為該研究提供了</span><span style="color: #ff0000;"><strong>PCF空間單細胞蛋白組</strong></span><span style="color: #0987e0;">檢測服務，助力研究者發現了眾多免疫細胞中，只有腫瘤相關巨噬細胞（TAM）和傷害感受神經元具有顯著的共定位關系，為揭示“TAM激活傷害感受神經元”的機制假說提供了直接的空間原位證據。</span></p> <section><img src="https://img.medsci.cn/e4345f172863f7232a9a7e6fb9bd7bc9493e3853d9fe894bbee0df89de3494ae.jpg" /></section> </section> </section> </section> <section> <section> <section> <section> <section> <section> <section></section> </section> <section> <section style="color: #0987e0;"><strong>0</strong><strong title="" data-original-title="">2</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作單位</strong>：上海長征醫院</span></p> <p><span style="color: #262626;"><strong>期刊名稱</strong>：</span><span style="color: #ff0000;"><strong>C</strong><strong>e</strong><strong>ll (IF:</strong><strong>42.5</strong><strong>)</strong></span></p> <p><span style="color: #262626;"><strong>文章標題</strong>：</span><span style="color: #262626;"><strong>An iPSC-derived CD19/BCMA CAR-NK therapy in a</strong><strong> </strong><strong>patient with systemic sclerosis</strong></span></p> <p><span style="color: #262626;">該研究設計并開發了iPSC來源的CD19/BCMA雙靶點的CAR-NK細胞產品QN-139b，并成功應用在一例難治性硬皮病患者中，為重癥自身免疫病提供了變革性治療方案。</span></p> <p><span style="color: #0987e0;">華盈生物為該研究提供了</span><span style="color: #ff0000;"><strong>LCM-MS</strong><strong>空間蛋白組</strong></span><span style="color: #0987e0;">檢測服務。LCM-MS空間蛋白組發現了CAR-NK灌輸后，在患者皮膚的基底層、汗腺層、上皮層和真皮膠原層中不同的生物學通路被激活，揭示了QN-139b通過雙靶點清除致病B細胞，可以重塑免疫穩態和逆轉組織纖維化。</span></p> <section><img src="https://img.medsci.cn/77d64b54c3467374adbea43a55d16e4a35904189e606888767683089eef53307.jpg" /></section> </section> </section> </section> <section> <section> <section> <section> <section> <section style="color: #0987e0;"><strong>0</strong><strong title="" data-original-title="">3</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作單位</strong>：復旦大學附屬華山醫院</span></p> <p><span style="color: #262626;"><strong>期刊名稱</strong>：</span><span style="color: #ff0000;"><strong><span class="">Cancer Cell</span> (IF:</strong><strong>44.5</strong><strong>)</strong></span></p> <p><span style="color: #262626;"><strong>文章標題</strong>：</span><span style="color: #262626;"><strong>Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy</strong></span></p> <p><span style="color: #262626;">該項研究探討了STING信號通路在腫瘤免疫治療中的復雜作用，特別是其誘導的腫瘤單核細胞中PD-L1的高表達對抗STING激動劑療法產生耐藥性的影響。</span></p> <p><span style="color: #0987e0;">華盈生物為該研究提供了</span><span style="color: #ff0000;"><strong>PEX100信號通路磷酸化<span class="">抗體芯片</span>檢測分析服務</strong></span><span style="color: #0987e0;">，系統解析了TLR2激活對STING下游JAK-STAT和NF-κB通路磷酸化水平的調控，為機制闡釋提供了關鍵證據。</span></p> <section><img src="https://img.medsci.cn/028ac4a857b5ddb97c50062985c518b046f723a892fa91b8bd14aeca614d5fa8.jpg" /></section> </section> </section> </section> </section> </section> </section> <section data-tools="135編輯器" data-id="157292"> <section> <section> <section> <section> <section> <section> <section style="color: #0987e0;"><strong>0</strong><strong title="" data-original-title="" data-num="2">4</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作單位</strong>：中國醫學科學院腫瘤醫院</span></p> <p><span style="color: #262626;"><strong>期刊名稱</strong>：</span><span style="color: #ff0000;"><strong>Signal Transduct Target Ther (IF: 52.7)</strong></span></p> <p><span style="color: #262626;"><strong>文章標題</strong>：</span><span style="color: #262626;"><strong>Characterization of the extrinsic and intrinsic signatures and therapeutic vulnerability of small cell lung cancers</strong></span></p> <p><span style="color: #262626;">這項研究全面描繪了小細胞肺癌（SCLC）的單細胞和空間圖譜，系統解析了SCLC的腫瘤微環境組成和癌細胞異質性，并首次報道了FAK剪接變體可作為SCLC的預后標志物和治療靶點。</span></p> <p><span style="color: #0987e0;">華盈生物為該研究提供了</span><span style="color: #ff0000;"><strong>PCF空間單細胞蛋白組</strong></span><span style="color: #0987e0;">檢測服務，助力研究者揭示了腫瘤組織和癌旁組織顯著差異的免疫微環境特征，并發現了對免疫治療反應不同的患者中，腫瘤細胞上抗原呈遞分子<span class="">MHC</span>表達的顯著異質性，為理解SCLC免疫逃逸機制提供了新視角。</span></p> <section><img src="https://img.medsci.cn/101926cb29d8f51d21361980c8e7f1483907dd5687c9554f11a18d78c19ce7be.jpg" /></section> </section> </section> </section> <section> <section> <section> <section> <section> <section> <section></section> </section> <section> <section style="color: #0987e0;"><strong>0</strong><strong title="" data-original-title="" data-num="3">5</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作單位</strong>：上海長海醫院</span></p> <p><span style="color: #262626;"><strong>期刊名稱</strong>：</span><span style="color: #ff0000;"><strong>Signal Transduct Target Ther (IF: 52.7)</strong></span></p> <p><span style="color: #262626;"><strong>文章標題</strong>：<strong>A novel long-acting C5a-blocking cyclic peptide prevents sepsis-induced organ dysfunction via effective blockade of the inflammatory cascade</strong></span></p> <p><span style="color: #262626;">這項研究開發和驗證了一種新型長效 C5a 阻斷環肽（Cp1）在防治膿毒癥中作用效果。</span></p> <p><span style="color: #0987e0;">華盈生物提供的</span><span style="color: #ff0000;"><strong>Luminex</strong><strong>細胞因子</strong><strong>檢測服務</strong></span><span style="color: #0987e0;">協助研究團隊全面評估了 Cp1 對炎癥級聯反應的阻斷效果。通過對小鼠血漿及腹腔灌洗液中多種細胞因子與趨化因子的廣譜篩查，證實了 Cp1 能顯著抑制 IL-6、TNF-α 等關鍵因子的表達，從而有效遏制“細胞因子風暴”。</span></p> <section><img src="https://img.medsci.cn/fe5dd7213d7fb50b3c2c281336296a5bd6ecd34a799693b7e2027ee40c03f04e.jpg" /></section> </section> </section> </section> <section> <section> <section> <section> <section> <section style="color: #0987e0;"><strong>0</strong><strong title="" data-original-title="" data-num="4">6</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作單位</strong>：清華大學</span></p> <p><span style="color: #262626;"><strong>期刊名稱</strong>：</span><span style="color: #ff0000;"><strong>Signal Transduct Target Ther (IF: 52.7)</strong></span></p> <p><span style="color: #262626;"><strong>文章標題</strong>：</span><span style="color: #262626;"><strong>Clinical investigation on nebulized human umbilical cord</strong><strong> </strong><strong>MSC-derived extracellular vesicles for pulmonary</strong><strong>fi</strong><strong>brosis</strong><strong> </strong><strong>treatment</strong></span></p> <p><span style="color: #262626;">該研究開發了一種安全、有效且臨床可行的霧化人臍帶間充質干細胞外泌體（hUCMSC-EVs）療法，為肺纖維化提供了一種新型無細胞治療策略。</span></p> <p><span style="color: #262626;">華盈生物為該研究提供了</span><span style="color: #ff0000;"><strong>外泌體</strong><strong>蛋白組學</strong><strong>檢測服務</strong></span><span style="color: #262626;">，揭示了hUCMSC-EVs蛋白富集到很多組織重構的生物學通路中。很多蛋白參與超高分子纖維組成，及細胞骨架組成，這些都與纖維化直接相關，為解釋hUCMSC-EVs參與肺組織的纖維化重建提供了分子層面的證據。</span></p> <section><img src="https://img.medsci.cn/c9c2b4de33e5ea1028496e3332d34819e1043d9e9bf5f214a82c10d6e8e139ac.jpg" /></section> </section> </section> </section> </section> </section> </section> <section data-tools="135編輯器" data-id="157292"> <section> <section> <section> <section> <section> <section> <section style="color: #0987e0;"><strong>0</strong><strong title="" data-original-title="" data-num="3">7</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作單位</strong>：華中科技大學同濟醫學院附屬同濟醫院</span></p> <p><span style="color: #262626;"><strong>期刊名稱</strong>：</span><span style="color: #ff0000;"><strong>J Hepatol (IF: 33)</strong></span></p> <p><span style="color: #262626;"><strong>文章標題</strong>：</span><span style="color: #262626;"><strong>TGM2-mediated histone serotonylation promotes HCC progression via MYC signalling pathway</strong></span></p> <p><span style="color: #262626;">該研究發現了核定位的谷氨酰胺轉移酶2（TGM2）介導的H3Q5ser 修飾通過MYC 信號通路促進肝細胞癌進展。TGM2可作為HCC的預后生物標志物，靶向其谷氨酰胺轉移酶活性可能是抑制HCC進展的有效策略。</span></p> <p><span style="color: #0987e0;">華盈生物為該研究提供了</span><span style="color: #ff0000;"><strong>20K人類蛋白組芯片</strong><strong>檢測</strong><strong>服務</strong></span><span style="color: #0987e0;">，助力研究團隊發現了轉錄中介因子TRIM28可以直接和TGM2結合。TRIM28可以介導TGM2向MYC募集，促進 H3Q5ser 修飾 MYC 靶基因。</span></p> <section><img src="https://img.medsci.cn/1f2f2a7fecbff14f48e68eb7681b6b744c26d140053635419b5e3866eae8ad5f.jpg" /></section> </section> </section> </section> <section> <section> <section> <section> <section> <section> <section></section> </section> <section> <section style="color: #0987e0;"><strong>08</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作單位</strong>：南方醫科大學珠江醫院</span></p> <p><span style="color: #262626;"><strong>期刊名稱</strong>：</span><span style="color: #ff0000;"><strong>Gut</strong><strong> (IF:</strong><strong>26.2</strong><strong>)</strong></span></p> <p><span style="color: #262626;"><strong>文章標題</strong>：</span><span style="color: #262626;"><strong>Gut microbial-derived N-acetylmuramic acid alleviates colorectal cancer via the AKT1 pathway</strong></span></p> <p><span style="color: #262626;">該研究揭示了一種特定的肽聚糖片段<span class="">N-乙酰胞壁酸</span>（NAM）通過靶向并阻斷AKT1磷酸化的方式調控下游信號通路，發揮治療結直腸癌的創新機制。</span></p> <p><span style="color: #0987e0;">華盈生物為該研究提供了</span><span style="color: #ff0000;"><strong>20K人類蛋白組芯片靶</strong><strong>點篩選</strong><strong>和SPR驗證</strong><strong>靶點結合的檢測服</strong><strong>務</strong></span><span style="color: #0987e0;">，助力研究團隊發現了AKT1是NAM的直接結合靶點蛋白。</span></p> <section><img src="https://img.medsci.cn/2fc19f5da74b002de61efe27ae7635f37e2f425a51600859f1d3a2a3c03ef5a1.jpg" /></section> </section> </section> </section> <section> <section> <section> <section> <section> <section style="color: #0987e0;"><strong>0</strong><strong title="" data-original-title="" data-num="5">9</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作單位</strong>：華中科技大學同濟醫學院</span></p> <p><span style="color: #262626;"><strong>期刊名稱</strong>：</span><span style="color: #ff0000;"><strong>Nat Commun (IF: 15.7)</strong></span></p> <p><span style="color: #262626;"><strong>文章標題</strong>：</span><span style="color: #262626;"><strong>High-content screening identifies ganoderic acid A as a senotherapeutic to prevent cellular senescence and extend healthspan in preclinical models</strong></span></p> <p><span style="color: #262626;">這項研究通過高內涵篩選發現了一種低毒性的抗衰老天然產物靈芝酸A，并證實了靈芝酸A能夠預防多個物種的衰老，為開發新型抗衰老藥物提供了新思路。</span></p> <p><span style="color: #0987e0;">華盈生物為該研究提供了</span><span style="color: #ff0000;"><strong>20K人類蛋白組芯片</strong><strong>檢測服務</strong></span><span style="color: #0987e0;">，助力研究團隊發現了靈芝酸A可以直接與TCOF1結合以維持核糖體穩態，從而減輕多種細胞衰老表型。</span></p> <section><img src="https://img.medsci.cn/2730a9cc80fa9ba363736eeaf174e93a345cc98c428a34d13c68ee3b3a196268.jpg" /></section> </section> </section> </section> </section> </section> </section> <section data-tools="135編輯器" data-id="157292"> <section> <section> <section> <section> <section> <section> <section style="color: #0987e0;"><strong>10</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作單位</strong>：首都兒科研究所</span></p> <p><span style="color: #262626;"><strong>期刊名稱</strong>：</span><span style="color: #ff0000;"><strong>Nat Commun (IF: 15.7)</strong></span></p> <p><span style="color: #262626;"><strong>文章標題</strong>：</span><span style="color: #262626;"><strong>Parallel comparison of T cell and B cell subpopulations of adenoid hypertrophy and tonsil hypertrophy of children</strong></span></p> <p><span style="color: #262626;">該研究首次在單細胞水平揭示了兒童腺樣體肥大與扁桃體肥大的免疫微環境差異，闡明了腺樣體以免疫抑制為主導、扁桃體以適應性免疫應答為主的機制。</span></p> <p><span style="color: #0987e0;">華盈生物提供的</span><span style="color: #ff0000;"><strong>Luminex 細胞因子檢測服務</strong></span><span style="color: #0987e0;">協助團隊對分選的 B 細胞與T 細胞分泌的關鍵細胞因子進行了深度分析，揭示了腺樣體肥大組織具有更強的免疫抑制特性及較弱的免疫反應能力。</span></p> <section><img src="https://img.medsci.cn/80da1cf2f923ed74468c394c12cefce6f8a5f14e47c8369181091e186238f561.jpg" /></section> </section> </section> </section> <section> <section> <section> <section> <section> <section> <section><strong style="color: #0987e0;">11</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作單位</strong>：北京大學腫瘤醫院</span></p> <p><span style="color: #262626;"><strong>期刊名稱</strong>：</span><span style="color: #ff0000;"><strong>Nat Commun (IF: 15.7)</strong></span></p> <p><span style="color: #262626;"><strong>文章標題</strong>：</span><span style="color: #262626;"><strong>Harnessing the FGFR2/NF2/YAP signaling-dependent necroptosis to develop an FGFR2/IL-8 dual blockade therapeutic strategy</strong></span></p> <p><span style="color: #262626;">該研究系統闡明了FGFR2抑制劑通過NF2-YAP-MST1軸誘導壞死性凋亡的機制，并揭示了IL-8/PD-L1介導的免疫逃逸。聯合FGFR2抑制劑與免疫檢查點阻斷劑的策略為ESCC治療提供了新方向，具有重要臨床轉化價值。</span></p> <p><span style="color: #0987e0;">華盈生物為該研究提供了</span><span style="color: #ff0000;"><strong>細胞因子檢測服務</strong></span><span style="color: #0987e0;">，助力研究團隊發現了壞死性凋亡通過IL-8上調PD-L1的表達，介導免疫逃逸。</span></p> <section><img src="https://img.medsci.cn/4a58b4b2e62ccbfdb204a39430a48ae8f41c7875f81dd4c86b4f701d05e1a909.jpg" /></section> </section> </section> </section> <section> <section> <section> <section> <section> <section style="color: #0987e0;"><strong>12</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作單位</strong>：南方醫科大學南方醫院</span></p> <p><span style="color: #262626;"><strong>期刊名稱</strong>：</span><span style="color: #ff0000;"><strong>Cancer Commun (IF: 24.9)</strong></span></p> <p><span style="color: #262626;"><strong>文章標題</strong>：</span><span style="color: #262626;"><strong>Targeting SPHK1 in macrophages remodels the tumor microenvironment and enhances anti-PD-1 immunotherapy efficacy in colorectal cancer liver metastasis</strong></span></p> <p><span style="color: #262626;">該項研究發現了腫瘤相關巨噬細胞高表達的SPHK1在結直腸癌肝轉移（CRLM）發生和進展中作用機制，并提示聯合SPHK1阻斷劑和抗PD-1治療可能成為一種有前途的治療方案。</span></p> <p><span style="color: #0987e0;">華盈生物為該研究提供了</span><span style="color: #ff0000;"><strong>Luminex細胞因子檢測服務</strong></span><span style="color: #0987e0;">，助力解析了腫瘤細胞通過分泌趨化因子征募SPHK1+ TAMs，為揭示SPHK1調控腫瘤免疫微環境的機制提供了關鍵證據。</span></p> <section><img src="https://img.medsci.cn/1adfab29dec6f345ba7d92f6ea722120b7bad1867cd78f1361cbb357b712322b.jpg" /></section> </section> </section> </section> </section> </section> </section> <section data-tools="135編輯器" data-id="157292"> <section> <section> <section> <section> <section> <section> <section style="color: #0987e0;"><strong>13</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作單位</strong>：華中科技大學同濟醫學院附屬協和醫院</span></p> <p><span style="color: #262626;"><strong>期刊名稱</strong>：</span><span style="color: #ff0000;"><strong>Sci Bull  (IF: 21.1)</strong></span></p> <p><span style="color: #262626;"><strong>文章標題</strong>：</span><span style="color: #262626;"><strong>Initial cardioplegic flush with crystalloid cardioplegia improves donor heart preservation and function via NR4A3 upregulation and metabolic reprogramming</strong></span></p> <p><span style="color: #262626;">該項研究提出了一種創新的供體心臟獲取和保存方法，使用晶體停搏液（CC）聯合威斯康星大學（UW）保存液。</span></p> <p><span style="color: #0987e0;">華盈生物為該研究提供了</span><span style="color: #ff0000;"><strong>PEX100信號通路磷酸化抗體芯片檢測分析服務</strong></span><span style="color: #0987e0;">，精準解析了CC+UW干預下心肌細胞信號通路的動態變化，揭示了該方法通過抑制NF-κB通路激活，減少炎癥反應與能量消耗，提升心臟保存效果。</span></p> <section><img src="https://img.medsci.cn/779e5b4980f645ec7123aa933f79176ee3bfdf639b1db7bc3dcf9799f3f936fa.jpg" /></section> </section> </section> </section> <section> <section> <section> <section> <section> <section> <section></section> </section> <section> <section style="color: #0987e0;"><strong>14</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作單位</strong>：中國人民解放軍總醫院</span></p> <p><span style="color: #262626;"><strong>期刊名稱</strong>：</span><span style="color: #ff0000;"><strong>J Clin Invest  (IF: 13.6)</strong></span></p> <p><span style="color: #262626;"><strong>文章標題</strong>：</span><span style="color: #262626;"><strong>Asparagine drives immune evasion in bladder cancer via RIG-I stability and type I IFN signaling</strong></span></p> <p><span style="color: #262626;">這項研究發現了在膀胱癌中，天然代謝物天冬酰胺可以直接結合RIG-I，促進其降解，從而抑制IFN信號和抗腫瘤免疫。提出了左旋天冬酰胺酶聯合抗PD-1治療的新策略。</span></p> <p><span style="color: #0987e0;">華盈生物提供的</span><span style="color: #ff0000;"><strong> Luminex細胞因子檢測服務</strong></span><span style="color: #0987e0;">協助團隊解析了腫瘤細胞與免疫微環境的互作機制。通過高通量篩選多種細胞因子與趨化因子，發現了抑制天冬酰胺可促進腫瘤細胞分泌CCL5，從而招募CD8+ T細胞浸潤，增強抗腫瘤免疫的分子機制。</span></p> <section><img src="https://img.medsci.cn/dc2139766ca2f6fa042924c5897485525b35c9188b358aceffeb0c218a6e543e.jpg" /></section> </section> </section> </section> <section> <section> <section> <section> <section> <section style="color: #0987e0;"><strong>15</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作單位</strong>：復旦大學附屬中山醫院</span></p> <p><span style="color: #262626;"><strong>期刊名稱</strong>：</span><span style="color: #ff0000;"><strong>J Exp Clin Cancer Res (IF:12.8)</strong></span></p> <p><span style="color: #262626;"><strong>文章標題</strong>：</span><span style="color: #262626;"><strong>The DCDC2/ENO1 axis promotes tumor progression and immune evasion in intrahepatic cholangiocarcinoma via activating FGL1-LAG3 checkpoint</strong></span></p> <p><span style="color: #262626;">該研究揭示了DCDC2是肝內膽管癌（ICC）的新型腫瘤相關抗原，其通過穩定ENO1蛋白，一方面促進腫瘤進展，另一方面通過FGL1-LAG3檢查點抑制CD8+T細胞功能。靶向該軸為ICC診斷和治療提供了新策略。</span></p> <p><span style="color: #0987e0;">華盈生物為該研究提供了</span><span style="color: #ff0000;"><strong>20K人類蛋白組芯片自身抗體篩選的檢測服務</strong></span><span style="color: #0987e0;">，助力研究團隊發現了血清中DCDC2自身抗體可作為早期診斷ICC的生物標志物。這為解析DCDC2是一種新型腫瘤相關抗原提供了強有力的證據支持。</span></p> <section><img src="https://img.medsci.cn/7db1b06444854e787cb6411ca60238c1f794e614b1f9408d364fdf1e78082773.jpg" /></section> </section> </section> </section> </section> </section> </section> <section data-tools="135編輯器" data-id="157292"> <section> <section> <section> <section> <section> <section> <section style="color: #0987e0;"><strong>16</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作單位</strong>：中山大學孫逸仙紀念醫院</span></p> <p><span style="color: #262626;"><strong>期刊名稱</strong>：</span><span style="color: #ff0000;"><strong><span class="">eBioMedicine</span> (IF: 10.8)</strong></span></p> <p><span style="color: #262626;"><strong>文章標題</strong>：</span><span style="color: #262626;"><strong>TCL1A in naïve B cells as a therapeutic target for type 1 diabetes</strong></span></p> <p><span style="color: #262626;">本研究發現了T1D患者早期B細胞的功能異常，尤其是naïve B細胞比例增加，且其AKT激酶共激活因子TCL1A表達上調。靶向TCL1A能降低naïve B細胞數量，改善葡萄糖耐量。該成果為T1D治療提供了新的潛在靶點和治療策略。</span></p> <p><span style="color: #0987e0;">華盈生物為該研究提供了</span><span style="color: #ff0000;"><strong>PEX100信號通路磷酸化抗體芯片檢測服務</strong></span><span style="color: #0987e0;">，助力研究團隊發現了TCL1A主要調PI3K/AKT途徑，揭示了TCL1A可以通過AKT2途徑調節B細胞的生存和增殖，促進了T1D中自身反應性B細胞的存活。</span></p> <p><img src="https://img.medsci.cn/8ef86fdfb78281e5795f6d7f0e7282e9ca46308a09120cd5e030c6d8c050ea11.jpg" /></p> </section> </section> </section> </section> </section> <p><span style="color: #262626;">回顧過去一年，我們倍感榮幸能夠參與到這場深刻改變生命科學認知邊界的進程中。從揭示疾病機制的分子基礎，到繪制組織功能的時空圖譜，每一項令人矚目的研究成果背后，都標志著我們對生命復雜性的理解又邁出了堅實的一步。</span></p> <p><span style="color: #262626;">展望未來，生命科學的探索將向著更整合、更動態、更空間精準的方向不斷深化。我們將繼續以前瞻性的視野，持續迭代與拓展我們的技術平臺——無論是蛋白組覆蓋的廣度和深度、還是空間分辨率與單細胞精度的極限，我們都將不懈追求。我們堅信，蛋白組學，特別是其空間與動態維度，將是解鎖下一輪生物學突破的核心鑰匙。</span></p> <p><span style="color: #262626;">我們期待，在新的一年里，繼續以最堅實的技術平臺、最專業的科學支持與最開放的協作精神，與每一位致力于探索未知的科學家并肩前行。讓我們攜手，共同將更多的科學假設轉化為顛覆性的發現，在描繪生命奧秘的宏偉藍圖上，增添更多決定性的筆觸。</span></p> <section> <section style="color: #0987e0000;"></section> <p style="color: #595959;"><span style="color: #0987e0;"><strong>業務咨詢400-869-2936或17316301592（微信同號）</strong></span></p> <section style="color: #0987e0000;" data-role="title" data-tools="135編輯器" data-id="101167"> <section> <section> <section> <section> <section style="color: #ffffff;" data-brushtype="text"> <p><span style="color: #000000;"><strong>相關文獻</strong></span></p> </section> </section> </section> </section> </section> </section> <p><span style="color: #262626;">1.Zhang, Y., et al., Cancer cells co-opt an inter-organ neuroimmune circuit to escape immune surveillance. Cell, 2025. 188(24):6754-6773.e29.</span></p> <p><span style="color: #262626;">2.Wang, X., et al., An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis. Cell, 2025. 188(16):4225-4238.e12.</span></p> <p><span style="color: #262626;">3.Song, H., et al., Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. Cancer Cell, 2025. 43(3):503-518.e10.</span></p> <p><span style="color: #262626;">4.Wang, G.Z., et al., Characterization of the extrinsic and intrinsic signatures and therapeutic vulnerability of small cell lung cancers. Signal Transduct Target Ther, 2025. 10(1):290.</span></p> <p><span style="color: #262626;">5.Luo, Z., et al., A novel long-acting C5a-blocking cyclic peptide prevents sepsis-induced organ dysfunction via effective blockade of the inflammatory cascade. Signal Transduct Target Ther, 2025. 10(1):362.</span></p> <p><span style="color: #262626;">6.Li, M., et al., Clinical investigation on nebulized human umbilical cord MSC-derived extracellular vesicles for pulmonary fibrosis treatment. Signal Transduct Target Ther, 2025. 10(1):179.</span></p> <p><span style="color: #262626;">7.Dong, R., et al., TGM2-mediated histone serotonylation promotes HCC progression via MYC signalling pathway. J Hepatol, 2025. 83(1):105-118.</span></p> <p><span style="color: #262626;">8.Hu, M., et al., Gut microbial-derived N-acetylmuramic acid alleviates colorectal cancer via the AKT1 pathway. Gut, 2025. 74(8):1230-1245.</span></p> <p><span style="color: #262626;">9.Chen, L., et al., High-content screening identifies ganoderic acid A as a senotherapeutic to prevent cellular senescence and extend healthspan in preclinical models. Nat Commun, 2025. 16(1):2878.</span></p> <p><span style="color: #262626;">10.Yu, Z., et al., Parallel comparison of T cell and B cell subpopulations of adenoid hypertrophy and tonsil hypertrophy of children. Nat Commun, 2025. 16(1):3516.</span></p> <p><span style="color: #262626;">11.Chen, D., et al., Harnessing the FGFR2/NF2/YAP signaling-dependent necroptosis to develop an FGFR2/IL-8 dual blockade therapeutic strategy. Nat Commun, 2025. 16(1):4128.</span></p> <p><span style="color: #262626;">12.Zhan, Y., et al., Targeting SPHK1 in macrophages remodels the tumor microenvironment and enhances anti-PD-1 immunotherapy efficacy in colorectal cancer liver metastasis. Cancer Commun (Lond), 2025. 45(10): 1203-1228.</span></p> <p><span style="color: #262626;">13.Wang, Y., et al., Initial cardioplegic flush with crystalloid cardioplegia improves donor heart preservation and function via NR4A3 upregulation and metabolic reprogramming. Sci Bull (Beijing), 2025. 70(10):1673-1690.</span></p> <p><span style="color: #262626;">14.Wei, W., et al., Asparagine drives immune evasion in bladder cancer via RIG-I stability and type I IFN signaling. J Clin Invest, 2025. 135(8). e186648.</span></p> <p><span style="color: #262626;">15.Wan W et al. The DCDC2/ENO1 axis promotes tumor progression and immune evasion in intrahepatic cholangiocarcinoma via activating FGL1-LAG3 checkpoint. J Exp Clin Cancer Res. 2025;44(1):177.</span></p> <p><span style="color: #262626;">16.Luo S et al. TCL1A in naïve B cells as a therapeutic target for type 1 diabetes. EBioMedicine. 2025;113:105593.</span></p> </section>